EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study

Mette Tiedemann Skipper iD, Niels Birkebæk, Rikke Beck Jensen, Bente Lomholt Langdahl, Ruta Tuckuviene, Peder Skov Wehner, Kjeld Schmiegelow iD, Thomas Leth Frandsen iD, Liv Andrés-Jensen, Birgitte Klug Albertsen iD

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Mette Tiedemann Skipper und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmar…. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Metabolic Syndrome, Blood Glucose. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Danish Cancer Research Foundation, NordForsk, Engineer Otto Christensen's Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic syndrome (MetS), a risk factor for early cardiovascular morbidity and mortality, is seen in up to 34% of survivors of childhood acute lymphoblastic leukemia (ALL). Procedure We performed a Danish, national cross‐sectional study of ALL survivors (aged 1–45 years at diagnosis) treated according to the NOPHO ALL2008 protocol, examined at least 1 year after treatment cessation. The study included non‐cancer community controls, matched on sex and age. We explored the prevalence and components of the MetS criteria (hyperglycemia, hypertension, increased waist circumference (WC), and dyslipidemia) and glucose homeostasis (insulin and C‐peptide).

Results

We included 366 survivors of ALL (participation rate 84%) and 368 controls. Median age (IQR) at follow‐up examination was 14.1 (10.8–21.8) years, and follow‐up time after the ALL diagnosis was 6.9 (4.7–9.1). The prevalence of MetS in survivors was 7.6% and in controls 3.8 % ( p = 0.039). The increased MetS prevalence was driven by ALL patients undergoing total body irradiation (TBI), and age and body mass index (BMI) percentile ≥95 at diagnosis ( p ≤ 0.01). The MetS prevalence in non‐TBI patients did not differ from controls ( p = 0.43), but non‐TBI patients more often fulfilled the MetS criteria WC and/or elevated high‐density lipoprotein ( p < 0.03). Survivors had higher serum insulin and C‐peptide than controls ( p < 0.01).

Conclusions

ALL survivors have an increased risk of MetS compared with controls, essentially driven by the patients treated with TBI. The MetS frequency in non‐TBI patients is equal to controls, but non‐TBI patients more often have one or two components of Mets. ALL survivors seem slightly more insulin‐resistant than controls.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaMetabolic SyndromeBlood GlucoseHumansMaleChildFemaleAdolescentYoung AdultChild, PreschoolCross-Sectional StudiesAdultInfantRisk FactorsFollow-Up StudiesMiddle AgedHomeostasisCancer SurvivorsCase-Control StudiesPrevalencePrognosisDenmark

Stichwörter der Autor:innen

acute lymphoblastic leukemialong‐term cancer survivorsmetabolic syndromepediatric hematology/oncologysequelae

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital-Herlev, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Endocrinology and Internal Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

ORCID-Profile: Mette Tiedemann Skipper, Kjeld Schmiegelow, Thomas Leth Frandsen, Birgitte Klug Albertsen

Förderung

  • The Danish Cancer Research Foundation
  • NordForsk
  • Engineer Otto Christensen's Foundation
  • Riisford Foundation
  • Merchant M. Brogaard and wife's Memorial Foundation
  • Aase and Ejnar Danielsen's Foundation
  • Health Research Foundation of Central Denmark Region
  • Aarhus University

Zitieren

APA

Skipper, M. T., Birkebæk, N., Jensen, R. B., Langdahl, B. L., Tuckuviene, R., Wehner, P. S., Schmiegelow, K., Frandsen, T. L., Andrés-Jensen, L., & Albertsen, B. K. (2025). Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31705

Vancouver

Skipper MT, Birkebæk N, Jensen RB, Langdahl BL, Tuckuviene R, Wehner PS, et al. Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31705

BibTeX
@article{Skipper2025,
  author = {Skipper, Mette Tiedemann and Birkebæk, Niels and Jensen, Rikke Beck and Langdahl, Bente Lomholt and Tuckuviene, Ruta and Wehner, Peder Skov and Schmiegelow, Kjeld and Frandsen, Thomas Leth and Andrés-Jensen, Liv and Albertsen, Birgitte Klug},
  title = {Risk of Metabolic Syndrome and Glucose Homeostasis Among Childhood and Young Adult Acute Lymphoblastic Leukemia Survivors: Part of the ALL‐STAR Study},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31705}
}
Kostenlos starten →